japanes
enceph
viru
jev
member
genu
flaviviru
famili
flavivirida
mosquitotransmit
zoonot
pathogen
caus
case
death
per
year
arbovirus
genu
flaviviru
includ
jev
dengu
viru
denv
west
nile
viru
wnv
yellow
fever
viru
jev
caus
sever
central
nervou
disord
poliomyelitislik
paralysi
asept
mening
enceph
human
fatal
rate
caus
jev
half
survivor
sever
neurolog
sequela
includ
persist
motor
defect
sever
cognit
languag
impair
geograph
rang
jev
still
expand
enhanc
threat
jev
infect
report
australia
pakistan
saipan
past
year
therefor
jev
still
import
pathogen
global
health
signific
inactiv
liveattenu
vaccin
use
prevent
jev
infect
mani
year
although
vaccin
reduc
incid
je
countri
seem
effect
clinic
isol
august
outbreak
jev
shanxi
provinc
china
caus
case
death
urgent
need
antivir
agent
reduc
death
toll
neurolog
sequela
jev
infect
two
antihepat
c
viru
drug
target
viral
proteas
telaprevir
develop
vertex
boceprevir
develop
merck
approv
variou
effect
inhibitor
denv
wnv
also
identifi
drug
candid
recent
studi
agent
found
good
antivir
effect
jev
indirubin
deriv
isati
indigotica
extract
prove
inhibitori
effect
jev
vitro
less
cytotox
dehydroepiandrosteron
dhea
suppress
replic
virusinduc
apoptosi
neuroblastoma
cell
act
extracellular
signalregul
protein
kinas
nnonyldeoxynojirimycin
affect
interact
calnexin
endoplasm
reticulum
chaperon
jev
glycoprotein
premembran
envelop
nonstructur
protein
thu
antijev
effect
vitro
vivo
sch
deriv
inhibit
plaqu
produc
jev
concentr
howev
current
small
number
jev
inhibitor
avail
drug
develop
studi
cytopathiceffect
cpe
base
highthroughput
screen
ht
assay
develop
discoveri
jev
antivir
inhibitor
use
screen
pharmacolog
activ
compound
three
compound
identifi
antivir
effect
jev
cell
cultur
dulbecco
modifi
eagl
medium
sigmaaldrich
st
loui
mo
usa
supplement
fetal
calf
serum
fc
invitrogen
grand
island
ny
usa
uml
penicillin
sigmaaldrich
streptomycin
sigmaaldrich
jev
strain
genbank
access
propag
cell
mainten
medium
contain
fc
uml
penicillin
streptomycin
cell
viabil
evalu
celltiterglo
luminesc
cell
viabil
assay
reagent
promega
madison
wi
usa
follow
manufactur
protocol
equal
volum
celltiterglo
reagent
ad
cell
white
plate
corn
tewksburi
usa
mix
min
orbit
shaker
incub
min
room
temperatur
luminesc
well
measur
microbeta
trilux
perkin
elmer
waltham
usa
percentag
cell
viabil
calcul
follow
percentag
cell
viabil
luminesc
experiment
groupluminesc
control
group
cell
densiti
assay
endpoint
infect
dose
ht
assay
optim
cell
differ
densiti
cell
per
well
infect
jev
variou
multipl
infect
moi
cell
viabil
detect
differ
time
h
jev
inocul
suitabl
cell
densiti
assay
endpoint
infect
dose
ht
assay
select
compar
cell
growth
sb
ratio
valu
differ
condit
valu
sb
ratio
calcul
previous
describ
cell
seed
onto
plate
cell
per
well
h
incub
cultur
supernat
replac
mainten
medium
one
microlit
compound
ad
mainten
medium
first
well
follow
twofold
serial
dilut
two
well
full
mix
third
well
medium
discard
mainten
medium
contain
moi
jev
ad
well
plate
subject
horizont
shake
achiev
thorough
mix
three
well
mockinfect
cell
well
three
well
jevinfect
cell
contain
dmso
set
plate
control
h
incub
percentag
cpe
inhibit
calcul
previous
describ
percentag
inhibit
luminesc
experiment
group
averag
luminesc
viru
control
averag
luminesc
cell
control
averag
luminesc
viru
control
cell
plate
infect
jev
moi
compound
ad
cell
final
concentr
incub
h
express
jev
envelop
e
protein
detect
western
blot
cell
collect
trypsin
digest
wash
pb
cell
suspens
mix
equal
volum
sampl
buffer
protein
electrophores
sdspage
transfer
nitrocellulos
filter
membran
millipor
darmstadt
germani
western
blot
perform
jev
e
proteinspecif
monoclon
antibodi
mab
construct
laboratori
gapdhspecif
mab
proteintech
chicago
il
usa
primari
antibodi
follow
addit
horseradishperoxidaseconjug
goat
antimous
igg
boster
wuhan
china
secondari
antibodi
final
protein
blot
detect
supersign
west
pico
chemiluminesc
substrat
thermo
scientif
rockford
il
usa
imag
mfchemibi
dnr
bioimag
system
mahal
hahamisha
israel
express
e
gapdh
quantifi
grayvalu
analysi
use
softwar
imagej
express
e
protein
normal
express
gapdh
chang
e
express
calcul
compar
noncompound
treat
group
cell
seed
plate
inocul
jev
moi
h
incub
compound
ad
cell
concentr
incub
h
viru
replic
cell
evalu
ifa
cell
fix
formaldehyd
min
incub
mab
fitcconjug
goat
antimous
antibodi
boster
min
respect
final
cell
stain
dapi
sigmaaldrich
imag
fluoresc
microscop
olympu
olympu
tokyo
japan
cell
plate
plate
densiti
cell
per
well
grown
h
cell
attach
cell
infect
jev
moi
presenc
differ
concentr
compound
concentr
assay
triplic
fortyeight
hour
postinfect
virus
group
harvest
freezingthaw
three
time
mix
tube
viru
suspens
inocul
cell
plate
plaqu
assay
previous
describ
antivir
mechan
compound
evalu
timeofaddit
assay
previous
describ
cell
seed
white
plate
cell
per
well
infect
jev
moi
h
incub
test
compound
ad
cell
h
preinfect
h
infect
h
h
postinfect
h
percentag
inhibit
group
evalu
h
postinfect
cell
seed
white
plate
cell
per
well
twelv
hour
later
growth
medium
replac
mainten
medium
contain
moi
jev
well
differ
concentr
compound
cell
incub
continu
h
percentag
inhibit
measur
describ
valu
calcul
nonlinear
regress
analysi
cell
seed
white
plate
cell
per
well
h
incub
cell
attach
differ
concentr
compound
ad
cell
cell
viabil
test
describ
h
incub
cytotox
concentr
calcul
nonlinear
regress
analysi
ht
assay
condit
includ
seed
cell
densiti
infect
dose
assay
endpoint
optim
compar
valu
sb
ratio
differ
condit
final
chose
cell
per
well
optim
cell
densiti
moi
optim
infect
dose
h
postinocul
endpoint
ht
optim
condit
three
independ
assay
perform
valid
robust
reproduc
ht
assay
valu
three
repeat
respect
averag
sb
valu
respect
averag
averag
coeffici
variat
cv
mockinfect
jevinfect
cell
respect
result
fit
well
standard
paramet
ht
demonstr
assay
robust
suitabl
largescal
compound
screen
cpebas
ht
assay
use
screen
jev
inhibitor
librari
pharmacolog
activ
compound
obtain
averag
valu
averag
sb
ratio
averag
cv
mockinfect
control
jevinfect
cell
ht
assay
inhibit
rate
compound
differ
concentr
calcul
end
assay
plot
figur
compound
identifi
inhibit
concentr
respect
compound
seven
compound
select
second
screen
accord
three
criterion
compound
inhibit
rate
compound
show
inhibitori
effect
jev
least
two
concentr
normal
cell
without
cytopathicchang
observ
microcopi
second
screen
four
compound
confirm
cpe
inhibit
two
concentr
figur
antivir
effect
three
commerci
avail
compound
cilnidipin
n
niclosamid
identifi
western
blot
ifa
plaqu
reduct
assay
timeofaddit
assay
subsequ
studi
cell
infect
jev
treat
three
compound
concentr
express
viral
e
protein
examin
western
blot
e
protein
express
mockinfect
control
figur
lane
wherea
obviou
band
found
jevinfect
cell
figur
lane
express
e
protein
clearli
decreas
compound
treatment
e
protein
detect
cilnidipin
group
figur
lane
grayvalu
analysi
e
express
decreas
treat
niclosamid
cilnidipin
cilnidipin
respect
figur
lane
jev
propag
cell
presenc
compound
h
postinfect
ifa
perform
assess
reproduct
jev
cell
fluoresc
signal
mockinfect
cell
figur
almost
cell
virusposit
jevinfect
cell
figur
jev
reproduct
could
inhibit
presenc
variou
compound
concentr
jevneg
cell
cilnidipin
niclosamidetr
group
respect
figur
e
g
absolut
inhibit
jev
replic
achiev
concentr
cilnidipin
reach
figur
simultan
cell
jevposit
treatment
niclosamid
figur
h
jevinfect
cell
treat
differ
concentr
compound
h
viru
replic
evalu
plaqu
assay
inhibitori
effect
compound
jev
replic
show
dosedepend
effect
figur
plaqu
pfuml
form
cell
treat
three
compound
figur
group
number
plaqu
also
pfuml
compound
concentr
figur
control
viru
titer
untreat
group
pfuml
data
show
compound
ad
jevinfect
cell
h
postinfect
percentag
inhibit
evalu
h
incub
inhibit
infect
detect
compound
ad
jev
attach
howev
antijev
activ
compound
observ
postinfect
group
figur
thu
three
compound
might
inhibit
jev
stage
viral
replic
quantifi
antivir
effect
inhibit
rate
three
compound
differ
concentr
determin
calcul
nonlinear
regress
inhibitori
effect
three
compound
show
dosedepend
pattern
cilnidipin
niclosamid
respect
figur
c
e
assess
cytotox
cell
viabil
differ
concentr
compound
test
cilnidipin
niclosamid
determin
figur
f
select
index
cilnidipin
niclosamid
respect
acquir
complet
cpe
induc
jev
endpoint
ht
assay
optim
h
postinocul
long
incub
period
pose
real
challeng
robust
repetit
ht
assay
optim
cell
densiti
infect
dose
cpebas
ht
show
high
reproduc
includ
averag
valu
suitabl
sb
ratio
around
variat
cell
control
viru
infect
control
addit
similar
sb
cv
valu
obtain
ht
compound
demonstr
assay
reliabl
larg
scale
screen
antivir
inhibitor
meanwhil
cpebas
assay
could
also
use
determin
compound
jev
quantifi
cytopath
effect
caus
jev
potenti
cytotox
inhibit
concentr
compound
librari
might
quit
differ
ht
choos
one
suitabl
concentr
compound
possibl
present
studi
evalu
inhibitori
effect
compound
three
concentr
compound
found
higher
inhibit
rate
compound
high
concentr
might
influenc
cell
viabil
thu
exhibit
lower
inhibit
rate
especi
analysi
three
test
compound
proven
less
cytotox
cell
fig
f
difficult
understand
inhibit
rate
compound
lower
antivir
mechan
three
hit
compound
explor
studi
three
compound
show
inhibitori
effect
postinfect
stage
use
timeofaddit
assay
figur
therefor
compound
inhibit
viru
process
replic
essenti
viral
protein
relat
replic
includ
proteas
helicas
methyltransferas
mtase
rnadepend
rna
polymeras
rdrp
studi
inhibitori
effect
compound
jev
proteas
helicas
test
fluoresc
reson
energi
transfer
fret
respect
previous
describ
compound
inhibit
two
protein
unpublish
data
potenti
antivir
target
may
mtase
rdrp
cellular
enzym
compound
inhibit
jev
replic
investig
cilnidipin
dual
blocker
l
ntype
calcium
channel
vascular
smooth
muscl
sympathet
nerv
termin
suppli
blood
vessel
effect
treatment
essenti
hypertens
approv
japan
toxic
cilnidipin
low
gkg
low
incid
unfavor
side
effect
human
present
studi
cilnidipin
also
show
effect
inhibit
jev
replic
jev
almost
complet
inhibit
cilnidipin
cilnidipin
might
candid
antijev
drug
anxiolyt
drug
act
peripher
benzodiazepin
receptor
produc
anxiolyt
effect
stimul
steroidogenesi
neuroact
steroid
allopregnanolon
present
studi
show
ideal
antivir
effect
concentr
high
select
index
illustr
could
inhibit
jev
high
specif
previou
studi
show
abil
enter
brain
therefor
might
inhibit
jev
brain
cell
could
potenti
drug
treatment
enceph
caus
jev
